Secondary cytoreduction against systemic chemotherapy in peritoneal recurrence of ovarian cancer. Critical analysis of results.

Melanie Morote González,Pablo Lozano, Laura Cebolla,Wenceslao Vásquez,Natividad Palencia,Luis González Bayón

Ejso（2022）

引用 0|浏览1

暂无评分

摘要

Background: The use of secondary debulking is accepted in patients with disease-free survival greater than 6 months after adjuvance with platinum, with peritoneal, lymph node and even liver recurrence, but controversy remains after the results of the latest controlled clinical trials published between 2019-2021 (GOG- 0123, DESKOPT III, SOC1).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要